GABA system: clinical research and treatment of tardive dyskinesia.
D000480:Alkynes; D000614:Aminocaproates / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D009118:Muscimol / Q000627:therapeutic use; D013378:Substantia Nigra / Q000503:physiopathology; D014635:Valproic Acid / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000502:physiology / Q000627:therapeutic use*
D000480:Alkynes; D000614:Aminocaproates; D007555:Isoxazoles; D001569:Benzodiazepines; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; C013785:4-amino-5-hexynoic acid; D014635:Valproic Acid; D020888:Vigabatrin; C015542:gaboxadol; D004298:Dopamine